

## Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 <sup>a</sup>
<b>MANDATORY INFORMATION</b>								
Unique identifier	6030	R085						
Donor age (years)	30.1	61						
Donor sex (M/F)	M	M						
Donor BMI (kg/m <sup>2</sup> )	27.1	30.5						
Donor HbA <sub>1c</sub> or other measure of blood glucose control	C-peptide 2.54 ng/mL	5.6						
Origin/source of islets <sup>b</sup>	nPOD	ADI IsletCore						
Islet isolation centre	U of Florida	U of Alberta						
Donor history of diabetes? Please select yes/no from drop down list								
<b>If Yes, complete the next two lines if this information is available</b>								
Diabetes duration (years)								
Glucose-lowering therapy at time of death <sup>c</sup>								

*Continues on the next page*

RECOMMENDED INFORMATION								
Donor cause of death	Head Trauma	NDD-Neurological						
Warm ischaemia time (h)	N/A	N/A						
Cold ischaemia time (h)	N/A	N/A						
Estimated purity (%)	N/A	N/A						
Estimated viability (%)	N/A	N/A						
Total culture time (h) <sup>d</sup>	N/A	N/A						
Glucose-stimulated insulin secretion or other functional measurement <sup>e</sup>	N/A	N/A						
Handpicked to purity? Please select yes/no from drop down list								
Additional notes	Pancreatic sections	Pancreatic sections						

<sup>a</sup>If you have used more than eight islet preparations, please complete additional forms as necessary

<sup>b</sup>For example, IIDP, ECIT, Alberta IsletCore

<sup>c</sup>Please specify the therapy/therapies

<sup>d</sup>Time of islet culture at the isolation centre, during shipment and at the receiving laboratory

<sup>e</sup>Please specify the test and the results